GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN

Celairis secures exclusive rights to commercialize Ocugen's investigational modifier gene therapy OCU400 for retinitis pigmentosa across Australia, New Zealand, & ASEAN markets.
The partnership expands potential access to a one-time treatment for RP in a region of approximately 725 million people following potential U.S. approval.
Ocugen will receive an upfront license fee, potential development & milestone payments totaling up to $7.1 million, a high single-digit percentage royalty on net sales, & 50% of gross profits from regional sales.
The $7.1 million payment package includes $6.1 million linked to the upfront fee & OCU400 top-line results expected in the first quarter of 2027.
Celairis will manage regional regulatory submissions, market access, & commercialization, while Ocugen will manufacture & supply OCU400 under a planned supply agreement.
OCU400 is currently in the Phase 3 liMeliGhT clinical trial for RP, with top-line data expected in Q1 2027 & global regulatory submissions planned thereafter.
The agreement marks Ocugen's third strategic regional partnership for OCU400, aimed at enhancing global patient access to its gene-agnostic modifier therapy platform.